343 related articles for article (PubMed ID: 32645244)
1. Potential Future Use, Costs, and Value of Poliovirus Vaccines.
Thompson KM; Kalkowska DA
Risk Anal; 2021 Feb; 41(2):349-363. PubMed ID: 32645244
[TBL] [Abstract][Full Text] [Related]
2. An economic analysis of poliovirus risk management policy options for 2013-2052.
Duintjer Tebbens RJ; Pallansch MA; Cochi SL; Wassilak SG; Thompson KM
BMC Infect Dis; 2015 Sep; 15():389. PubMed ID: 26404632
[TBL] [Abstract][Full Text] [Related]
3. Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):364-375. PubMed ID: 33590519
[TBL] [Abstract][Full Text] [Related]
4. Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):266-272. PubMed ID: 32144841
[TBL] [Abstract][Full Text] [Related]
5. The risks, costs, and benefits of possible future global policies for managing polioviruses.
Thompson KM; Tebbens RJ; Pallansch MA; Kew OM; Sutter RW; Aylward RB; Watkins M; Gary HE; Alexander J; Jafari H; Cochi SL
Am J Public Health; 2008 Jul; 98(7):1322-30. PubMed ID: 18511720
[TBL] [Abstract][Full Text] [Related]
6. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.
Kalkowska DA; Pallansch MA; Wilkinson A; Bandyopadhyay AS; Konopka-Anstadt JL; Burns CC; Oberste MS; Wassilak SGF; Badizadegan K; Thompson KM
Risk Anal; 2021 Feb; 41(2):329-348. PubMed ID: 33174263
[TBL] [Abstract][Full Text] [Related]
7. Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.
Kalkowska DA; Pallansch MA; Cochi SL; Kovacs SD; Wassilak SGF; Thompson KM
Risk Anal; 2021 Feb; 41(2):320-328. PubMed ID: 32632925
[TBL] [Abstract][Full Text] [Related]
8. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV).
Thompson KM; Kalkowska DA
Expert Rev Vaccines; 2019 Jul; 18(7):725-736. PubMed ID: 31248293
[No Abstract] [Full Text] [Related]
9. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
Orenstein WA;
Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
[TBL] [Abstract][Full Text] [Related]
10. Cost analysis of post-polio certification immunization policies.
Sangrujee N; Cáceres VM; Cochi SL
Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
[TBL] [Abstract][Full Text] [Related]
11. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
Thompson KM; Duintjer Tebbens RJ
BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
[TBL] [Abstract][Full Text] [Related]
12. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):312-319. PubMed ID: 32936466
[TBL] [Abstract][Full Text] [Related]
13. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.
Duintjer Tebbens RJ; Thompson KM
Expert Rev Vaccines; 2018 Aug; 17(8):739-751. PubMed ID: 30056767
[TBL] [Abstract][Full Text] [Related]
14. An Updated Economic Analysis of the Global Polio Eradication Initiative.
Thompson KM; Kalkowska DA
Risk Anal; 2021 Feb; 41(2):393-406. PubMed ID: 33590521
[TBL] [Abstract][Full Text] [Related]
15. Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.
Thompson KM; Kalkowska DA
Risk Anal; 2021 Feb; 41(2):229-247. PubMed ID: 32339327
[TBL] [Abstract][Full Text] [Related]
16. Projection of Costs of Polio Eradication Compared to Permanent Control.
Zimmermann M; Hagedorn B; Lyons H
J Infect Dis; 2020 Feb; 221(4):561-565. PubMed ID: 31565733
[TBL] [Abstract][Full Text] [Related]
17. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2018 Apr; 18(1):165. PubMed ID: 29631539
[TBL] [Abstract][Full Text] [Related]
18. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.
Famulare M; Selinger C; McCarthy KA; Eckhoff PA; Chabot-Couture G
PLoS Biol; 2018 Apr; 16(4):e2002468. PubMed ID: 29702638
[TBL] [Abstract][Full Text] [Related]
19. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071
[TBL] [Abstract][Full Text] [Related]
20. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.
Thompson KM; Kalkowska DA; Duintjer Tebbens RJ
Vaccine; 2015 Mar; 33(13):1568-77. PubMed ID: 25701673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]